The explosion of emerging cell and gene therapy programs that modify and reprogram a patient’s own cells has created immense opportunity for treating intractable diseases. However, high treatment costs, a complex supply chain, and limited payer budgets and treatment reimbursement have created an unsustainable manufacturing and treatment delivery model that is forcing the biopharmaceutical industry to reconsider its approach.

Lupagen’s closed-loop, patient-connected, bedside point-of care system provides a better alternative to harnessing a patient’s cells, while keeping costs in line with conventional biologics therapies.

© 2019 by Lupagen